Controversial 'three-parent baby' technology could pose health risks to males
Newly proposed controversial IVF treatment, which avoids the risk of passing on inherited defects, could have health dangers, especially for males, according to a team of scientists led by the University of Sheffield.
Mitochondrial replacement therapy (MR) involves replacing the mother's damaged mitochondria by that of a healthy donor. This would effectively create a baby with DNA from three parents but remove the mother's mutated DNA to prevent the female from passing on these mutations.
The mitochondria supply cells with power but mutations in the mitochondria may result in inherited mitochondrial diseases which range from mild learning difficulties to debilitating conditions such as muscular dystrophy and other life-threatening heart, muscle and brain diseases. Each year one in 200 children in the UK are born with any such mutation and one in 4000 develops a mitochondrial disease.
MR is a controversial technique because it involves germ line modification of the embryo's DNA. This means that the third party's genetic material will not only be passed on to the child but also to future generations down the female line.
Earlier suggestions that replacing mitochondria is nothing more than replacing the batteries of a camera may well need to be reconsidered.
The research team led by Dr Klaus Reinhardt, from the University of Sheffield's Department of Animal and Plant Sciences, in collaboration with Dr Ted Morrow from the University of Sussex and Dr Damian Dowling from Monash University in Australia, compiled evidence that indicates MR can profoundly change the expression of the normal DNA.
A donor's mitochondria may therefore affect a range of important traits such as individual development, cognitive behaviour and key health parameters in the recipient.
"Many combinations of normal DNA and mitochondria don't work so well together. For MR, we need to consider that every person is a different camera. Simply inserting new batteries can lead to complication, even if the donor is perfectly healthy", said Dr Reinhardt.
"Complications occur more often in males because mitochondria are only passed down from mothers, never from fathers. Any negative effects of mitochondria on a male's DNA can, therefore, never be removed by evolution."
If detailed proposals regulating the MR procedure pass a public consultation and are approved by Parliament next year, the world's first three-parent baby could be born in Britain by 2015.
Dr Reinhardt added: "This technology has the potential to allow affected mothers to have healthy babies. Continuing some of the promising research avenues may be an important step towards the safety of this technology."
Mitochondrial Replacement, Evolution, and the Clinic is published in Policy Forum in Science (www.science.org) on September 20.
The research was conducted by Dr Klaus Reinhardt from the University of Sheffield, and Tuebingen, Dr Ted Morrow from the University of Sussex and Dr Damian Dowling Monash University, Australia.
The University of Sheffield
With nearly 25,000 of the brightest students from 117 countries coming to learn alongside 1,209 of the world’s best academics, it is clear why the University of Sheffield is one of the UK’s leading universities. Staff and students at Sheffield are committed to helping discover and understand the causes of things - and propose solutions that have the power to transform the world we live in.
A member of the Russell Group, the University of Sheffield has a reputation for world-class teaching and research excellence across a wide range of disciplines. The University of Sheffield has been named University of the Year in the Times Higher Education Awards 2011 for its exceptional performance in research, teaching, access and business performance. In addition, the University has won four Queen’s Anniversary Prizes (1998, 2000, 2002, 2007), recognising the outstanding contribution by universities and colleges to the United Kingdom’s intellectual, economic, cultural and social life.
One of the markers of a leading university is the quality of its alumni and Sheffield boasts five Nobel Prize winners among former staff and students. Its alumni have gone on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields.
Research partners and clients include Boeing, Rolls-Royce, Unilever, Boots, AstraZeneca, GSK, Siemens, Yorkshire Water and many more household names, as well as UK and overseas government agencies and charitable foundations.
The University has well-established partnerships with a number of universities and major corporations, both in the UK and abroad. The White Rose University Consortium (White Rose) a strategic partnership between 3 of the UK's leading research universities of Leeds, Sheffield and York. Since its creation in 1997 White Rose has secured more than £100M into the Universities.
For further information please contact
Media Relations Officer
University of Sheffield
0114 222 9851